Medtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions

Rhea-AI Summary

Medtronic (NYSE: MDT) announced that BrainSense Adaptive Deep Brain Stimulation (aDBS) was named a 2025 TIME Best Inventions. The sensing-enabled Percept neurostimulator with BrainSense personalizes Parkinson's therapy by adjusting stimulation in real time.

Medtronic said it received both CE Mark and U.S. FDA approval for BrainSense aDBS earlier in 2025, published pivotal results in JAMA Neurology (ADAPT-PD) showing clinical effectiveness, and reported that more than 1,000 patients worldwide have received adaptive therapy.

Positive

• U.S. FDA and CE Mark approvals for BrainSense aDBS in 2025
• ADAPT-PD published in JAMA Neurology showing effectiveness
• More than 1,000 patients treated with BrainSense adaptive therapy
• Medtronic has served 200,000+ DBS patients since 1987

Negative

• None.

News Market Reaction

-1.40%

1 alert

-1.40% News Effect

On the day this news was published, MDT declined 1.40%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

TIME Best Inventions honors extraordinary innovations changing lives

DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first closed-loop DBS system for people with Parkinson's – has been recognized by TIME on its annual list of Best Inventions.

There are over 10 million people living with Parkinson's disease globally,¹ and while there is currently no cure, Medtronic deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. Medtronic recently enhanced its Percept™ DBS neurostimulators with exclusive BrainSense™ Adaptive technology^† for people with Parkinson's. This feature personalizes therapy based on a patient's brain activity in real time – minimizing the need for patients to manually adjust stimulation.

For over two decades, TIME has recognized the products, software, and services shaping the world – from breakthroughs in science and technology to innovations that make daily life smarter, easier, and more sustainable. This year's honorees span notable categories from artificial intelligence and immersive technology to accessibility, logistics, and healthcare. All entries are thoughtfully assessed by TIME's esteemed editors on impact, innovation, and success.

Medtronic spent more than twenty years developing a complete, sensing-enabled DBS system leveraging exclusive BrainSense™ technology to detect, capture, and classify different brain signals. This advancement put Medtronic at the forefront of incorporating therapeutic brain-computer interface (BCI) technology into DBS therapy and BrainSense™ Adaptive DBS presents the largest commercial launch of BCI technology – ever. 

"Medtronic BrainSense™ Adaptive Deep Brain Stimulation marks a new era in neuromodulation and the use of therapeutic brain-computer interface technology to restore human health. We congratulate Medtronic on joining this year's esteemed list of Best Inventions." — TIME Editors, Best Inventions 2025

Medtronic received both CE Mark and U.S. FDA approval for BrainSense™ aDBS earlier this year and already more than 1,000² patients worldwide have received the adaptive therapy. Recently, the pivotal ADAPT-PD study was published in the Journal of the American Medical Association (JAMA) Neurology showing clinical effectiveness, long-term safety, and patient preference for Medtronic BrainSense™ aDBS³.

"We're honored that our BrainSense™ Adaptive DBS technology for people with Parkinson's is being recognized as one of the year's most important medical innovations," said Paolo Di Vincenzo, president of the Neuromodulation business, which is part of the Neuroscience portfolio at Medtronic. "This groundbreaking technology represents intentional innovation that responds to a patient's changing needs, equips clinicians with unparalleled insights, and sets a new standard for DBS therapy."

Since 1987, Medtronic has served more than 200,000 patients with movement disorders and other indications in more than 70 countries with its life-changing DBS therapy².

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Naomi Rodiles
Public Relations
+1-612-427-5521

Ryan Weispfenning
Investor Relations
+1-763-505-4626

^†The sensing feature of the Percept™ PC and Percept™ RC system is intended for use in patients receiving DBS where chronically recorded bioelectric data may provide useful, objective information regarding patient clinical status.

References:

1. Luo, Y., Qiao, L., Li, M., Wen, X., Zhang, W., & Li, X. (2025). Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Frontiers in aging neuroscience, 16, 1498756.
2. Medtronic data on file
3. Bronte-Stewart, H. M., Beudel, M., Ostrem, J. L., Little, S., Almeida, L., Ramirez-Zamora, A., ... & ADAPT-PD Investigators. (2025). Long-Term Personalized Adaptive Deep Brain Stimulation in Parkinson Disease: A Nonrandomized Clinical Trial. JAMA neurology.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-brainsense-adaptive-deep-brain-stimulation-named-a-2025-time-best-inventions-302579866.html

SOURCE Medtronic plc

FAQ

What recognition did Medtronic BrainSense aDBS receive on October 9, 2025?

BrainSense Adaptive DBS was named a 2025 TIME Best Inventions.

Has Medtronic received regulatory approval for BrainSense aDBS (MDT) in 2025?

Yes; Medtronic announced both a CE Mark and U.S. FDA approval earlier in 2025.

What clinical evidence supports Medtronic BrainSense aDBS for Parkinson's (MDT)?

The pivotal ADAPT-PD study was published in JAMA Neurology, reporting clinical effectiveness and long-term safety.

How many patients have received Medtronic BrainSense adaptive therapy worldwide?

Medtronic reported that more than 1,000 patients worldwide have received the adaptive therapy.

How does BrainSense Adaptive DBS personalize stimulation for Parkinson's patients?

BrainSense uses real-time sensing of brain activity to adjust stimulation automatically, reducing manual adjustments.

How extensive is Medtronic's experience with DBS therapy (MDT)?

Medtronic stated it has treated over 200,000 patients with DBS since 1987 across 70+ countries.